StreetInsider.com News Articles

Immunocore doses first patient in type 1 diabetes Phase 1 trial

Thu, 15 Oct 2026 07:00:25 -0400

Immunocore Holdings plc (Nasdaq: IMCR) announced that the first patient with type 1 diabetes has been dosed in a Phase 1 trial of IMC-S118AI, the company's first autoimmune disease candidate.

IMC-S118AI is a bispecific molecule designed to down-modulate the immune system in a tissue-specific manner to protect beta cells under T cell attack in type 1 diabetes. One end of the molecule binds to a preproinsulin peptide presented by HLA-A*02:01 on beta cells, while the other end is a PD-1 agonist effector arm designed to suppress autoreactive T cells.

The Phase 1 dose escalation trial will evaluate the safety, pharmacokinetics, and clinical

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

Thu, 15 Oct 2026 07:00:00 -0400

Immunocore announces first patient dosed in the Phase 1 trial of

IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

The Phase 1 trial will assess the safety and clinical activity of IMC-S118AI in HLA-A*02:01-positive patients with type 1 diabetes

Preclinical data supporting unique mechanism of action recently published
in Science Advances

(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 15 October 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

Thu, 15 Oct 2026 07:00:00 -0400

Immunocore announces first patient dosed in the Phase 1 trial of

IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

The Phase 1 trial will assess the safety and clinical activity of IMC-S118AI in HLA-A*02:01-positive patients with type 1 diabetes

Preclinical data supporting unique mechanism of action recently published
in Science Advances

Form SCHEDULE 13G/A Immunocore Holdings plc Filed by: FMR LLC

Wed, 07 Oct 2026 11:47:00 -0400

si-local-file:///var/storage/secattach/20261007/27159988.html

Form 8-K Immunocore Holdings plc For: Sep 14

Mon, 14 Sep 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260914/27055311.html

Immunocore completes enrollment in Phase 3 melanoma trial

Mon, 14 Sep 2026 07:01:04 -0400

Immunocore Holdings plc (Nasdaq: IMCR) announced it has reached its target enrollment of 540 patients in the TEBE-AM clinical trial (NCT05549297), a Phase 3 registrational study evaluating KIMMTRAK (tebentafusp) in previously treated advanced melanoma.

The global, randomized trial tests tebentafusp as a monotherapy and in combination with pembrolizumab, compared against Investigator's Choice, in HLA-A*02:01-positive patients whose disease progressed following prior therapy. The trial's primary endpoint is overall survival. Enrolled patients will continue to be followed for the planned overall survival analysis, with topline data expected as early as the end of 2026.

The trial includes patients with second-line or later advanced melanoma

Immunocore completes enrollment in Phase 3 melanoma trial

Mon, 14 Sep 2026 07:01:04 -0400

The trial includes patients with second-line or later advanced melanoma

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Mon, 14 Sep 2026 07:00:00 -0400

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK^® (tebentafusp) in previously treated advanced melanoma

Topline overall survival data expected as early as end of 2026

(OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced the achievement of target patient enrollment (540 patients) in the TEBE-AM clinical trial (NCT05549297).

TEBE-AM

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Mon, 14 Sep 2026 07:00:00 -0400

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK^® (tebentafusp) in previously treated advanced melanoma

Topline overall survival data expected as early as end of 2026

TEBE-AM

Immunocore to present at upcoming investor conferences

Tue, 01 Sep 2026 07:00:00 -0400

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.

Cantor Global Healthcare Conference 2026
Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m. EDT

Morgan Stanley 24^th Annual Global Healthcare Conference
Fireside Chat: Monday, September 14, 2026,

Immunocore to present at upcoming investor conferences

Tue, 01 Sep 2026 07:00:00 -0400

Immunocore to present at upcoming investor conferences

Cantor Global Healthcare Conference 2026
Fireside Chat: Thursday, September 10, 2026, at 2:45 p.m. EDT

Morgan Stanley 24^th Annual Global Healthcare Conference
Fireside Chat: Monday, September 14, 2026,

TD Cowen Assumes Immunocore Holdings (IMCR) at Buy

Sat, 22 Aug 2026 07:55:34 -0400

TD Cowen analyst Nic assumes coverage on Immunocore Holdings (NASDAQ: IMCR) with a Buy rating and a price target of $60.00.

For an analyst ratings summary and ratings history on Immunocore Holdings click here. For more ratings news on Immunocore Holdings click here.

Shares of Immunocore Holdings closed at $36.88 yesterday.

JPMorgan Reinstates Immunocore Holdings (IMCR) at Overweight

Fri, 21 Aug 2026 03:28:14 -0400

JPMorgan analyst Jessica Fye reinstates coverage on Immunocore Holdings (NASDAQ: IMCR) with a Overweight rating and a price target of $50.00.

For an analyst ratings summary and ratings history on Immunocore Holdings click here. For more ratings news on Immunocore Holdings click here.

Shares of Immunocore Holdings closed at $36.28 yesterday.

The Galien Foundation Announces 2026 International Prix Galien Award Nominees